Evidence map›Paper›PMID 42270775›Full record

ArticleOncogene2026

Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRAS

Yanjing Zhu, Chi Zhang, Min Li, Luoyan Ai, Fan Xu, Yiyi Yu, Shan Yu, Xiaojing Xu, Qing Liu, Mengxuan Zhu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yanjing Zhu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chi Zhang *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Min Li *Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-0523-9171
Luoyan Ai *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fan XuCancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-8751-3364
Yiyi YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-8444-0235
Shan YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaojing XuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qing LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengxuan ZhuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengling LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingyuan WangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0006-6931-0359
Yutong LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenghang XuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Haojie ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Huishan LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Rui WuResearch Institute of General Surgery, Jinling Hospital, Affiliated Hospital of Medicine School, Nanjing University, Nanjing, China. smmuwurui@163.com.ORCID http://orcid.org/0000-0001-7910-6614
Ke PengDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. peng.ke@zs-hospital.sh.cn.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.tianshu@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-8604-6311

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial advances in targeting KRAS

Indexed as

Activating Transcription Factor 3AsparagineDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)AnimalsAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell Line, TumorHumansIntegrated Stress ResponseMetabolic ReprogrammingMiceActivating Transcription Factor 3ASNS protein, humanAsparagineAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID42270775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.